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 What are the possible explanations of 
the inconsistent results obtained with 
these biomarkers? Some studies 2,3 show 
AUC values greater than 0.9 but, although 
truly positive, suff er from problems of 
generalizability, as they include homo-
geneous populations with a well-defi ned 
single injury to the kidney and with little 
or no additional comorbidity. In more 
heterogeneous populations such as adult 
cardiac surgery and, certainly, general 
ICU patients, the performance of biomar-
kers to detect AKI declines rapidly, with 
much lower AUC values. 1,4,5 Th e poor 
performance of urinary biomarkers in 
more general clinical conditions has 
recently been confirmed by Metzger 
 et al. 6 and could be overcome only by use 
of a panel of 20 urinary peptides. Th e 
novelty of the paper by Endre  et al. 1 is 
their attempt to evaluate whether specifi c 
biomarkers might perform better in spe-
cifi c clinical conditions — for example, in 
patients with versus without preexisting 
kidney disease, or with diff ering (pre-
sumed) timing of the kidney injury. 
Although this strategy indeed improved 
the results, enthusiasm is tempered by 
some more in-depth considerations. 
First, these new  ‘ categorized criteria ’ are 
 ‘ predictions of the past ’ and need to be 
validated in diff erent populations. Expe-
rience teaches that diagnostic accuracy 
plummets at such validation procedures. 
In addition, all the biomarkers in the 
EARLYARF trial have been determined 
in nearly ideal research environments. 
Th e switch to commercial kits will fur-
ther add to the diagnostic inaccuracy, 
along with the variability of the cutoff  
values of diff erent markers as reported in 
many studies. 7  Second, although the 
stratifi cation criteria applied by Endre 
 et al. 1 — underlying kidney function and 
timing of insult — seem to make sense, 
the time to insult had to be estimated for 
a substantial part of the population, and 
in clinical practice this information is 
oft en lacking. Th e majority of deaths aft er 
AKI occur in patients in whom the time 
of the renal insult is unknown. 8 Moreo-
ver, not knowing the time of insult is 
most problematic in patients with smol-
dering disease, such as sepsis — exactly 
the patient population that would bene-
fi t most from a robust AKI marker. In 
 “ When you search in the stars for 
what lies before your feet you risk to 
stumbling over the cobblestones. ” 
 freely translated from 
Schopenhauer 
 (Source: Internet quotes) 
 Urinary biomarkers in the fi eld of acute 
kidney injury (AKI) are a hot topic. A 
PubMed search using the terms  ‘ biological 
marker, urine ’ and  ‘ kidney injury, acute ’ 
revealed 158 papers on humans published 
in the past 24 months. Th e large majority, 
as well as their accompanying editorials, 
start or end with a statement that  ‘ urinary 
biomarker X ’ is very promising for clinical 
management of AKI and detection of 
renal damage before a fall in glomerular 
 fi ltration rate is noticeable from a rise in 
serum creatinine (SCr) and / or urinary 
output. Do the data really support this 
optimistic view, and can unrestricted 
implementation of biomarkers in clinical 
practice be recommended at present? 
 Th e paper by Endre  et al. 1 in this issue of 
 Kidney International does not support this 
view. In patients admitted to the intensive 
care unit (ICU), the areas under the 
receiver operating characteristic curves 
(AUCs) of biomarkers were compared for 
diagnosis and prediction of AKI, need of 
renal replacement therapy (RRT), and / or 
mortality. Th e overall performance of the 
six biomarkers was poor, taking into 
account that an AUC of 0.5 reflects the 
diagnostic accuracy of random allocation. 
 Figure 1 and  Table 1 show the AUC 
 values of diff erent biomarkers, clinical 
scores, and routine biochemical para-
meters (RIFLE classifi cation or Screa) as 
retrieved from human studies on AKI. A 
huge variation in the values is obvious. 
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 We discuss the performance of novel biomarkers in acute kidney injury 
(AKI). Comparison of the areas under the receiver operating 
characteristic curves of several biomarkers with some clinical and / or 
routine biochemical outcome parameters reveals that none of the 
biomarkers has demonstrated a clear additional value beyond the 
traditional approach in clinical decision making in patients with AKI.  
Unscrutinized use of these biomarkers may distract from adequate 
clinical evaluation and carries the risk of worse instead of better 
patient outcome. 
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 addition, the performance of neutrophil 
gelatinase-associated lipo calin (NGAL), 
for instance, was best 12 – 36  h after 
injury, 1 far from the pro mised  ‘ early diag-
nosis ’ ; it is unclear whether this is earlier 
than with other, more readily available 
markers such as the RIFLE or Acute Kid-
ney Injury Network criteria, based on 
urinary output 9 or increase of SCr. In 
view of the increasing incidence of acute-
on-chronic kidney disease, the poor per-
formance of bio markers, at least NGAL, 
in patients with preexisting CKD seems 
problematic. 4 Th is apparently leads to the 
 sobering conclusion that biomarkers 
seem to perform best in those patients 
and circumstances in which the need for 
them is the least. 
 There are more fundamental issues 
that need to be addressed in the discus-
sion on the place of biomarkers in AKI. 
First, a biomarker is useful only if it adds 
value beyond the currently available 
diagnostic armamentarium. It is at 
present unclear whether a biomarker 
performs better than the clinical exper-
tise of the treating physician or basic 
markers such as SCr or urinary output. 
Although Koyner  et al. 10 were unable to 
predict AKI using urinary NGAL and 
cystatin C, a very high predictive power 
was found for need of RRT. One won-
ders, however, whether clinical evalua-
tion would not predict this outcome 
equally well. Alterations in urine fl ow 
appeared to be a sensitive and early 
marker of renal dysfunction in ICU 
patients, 9 while, for example, extracor-
poreal perfusion time or clinical 
appraisal predicted AKI in patients aft er 
coronary bypass with the same perform-
ance as plasma interleukin-18. 11 In 
patients  presenting with signs of incipi-
ent sepsis at the emergency department, 
baseline SCr had an AUC of 0.72 for pre-
dicting AKI. 12 Th ese data are remarkably 
comparable to those of Nickolas  et al. 13 
In their study, the sensitivity of baseline 
SCr and urinary NGAL was comparable, 
but NGAL had a higher specifi city. As 
only 30 of 661 patients developed AKI, a 
fl owchart with use of SCr as fi rst line and 
of NGAL for confi rmation as second line 
seems a more optimal and more cost-
effi  cient approach than unscrutinized 
screening in everyone. According to Han 
 et al. , 14 change in SCr was at least as 
accurate as NGAL and kidney injury 
molecule-1 (KIM-1) in determining 
AKI, and Siew  et al. 5 found that NGAL 
added only in a limited way to clinical 
prediction in discriminating AKI in a 
general ICU population. If biomarkers 
ever play a role in clinical practice, they 
very likely should become part of a deci-
sion tree preceded by thorough clinical 
appraisal and simple biochemical mark-
ers. Blind unscrutinized use of biomark-
ers may distract from clinical evaluation 
and carries a risk of worse instead of bet-
ter outcomes. Studies evaluating the per-
formance of biomarkers should thus 
compare their performance with that of 
clinical appraisal. 
 Finally, Endre  et al. 1 point to the high 
negative predictive power of biomarkers 
for AKI with need of RRT: an astonishing 
97 % . However, as only 19 of 528 patients 
did develop the need for RRT, the ques-
tion may be raised of how many of those 
19 patients would have escaped dialysis if 
a  ‘ super-performing ’ biomarker had made 
the diagnosis earlier than occurred in 
the current setting of  ‘ normal clinical 
practice. ’ 
 In conclusion, biomarkers can be of use 
in the unraveling of biochemical and bio-
logical processes during AKI. However, 
the optimism about their use in the 
approach of clinical AKI seems at present 
to be not warranted. We believe that fi rst 
of all a careful clinical appraisal is still the 
mainstay of diagnosis and therapy. So far, 
in our opinion, none of the biomarkers 
has demonstrated a clear additional value 
in the clinical decision process. Their 
unlimited use risks distracting from 
important clinical evaluation, resulting in 
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 Figure 1  |  Areas under the receiver operating characteristic curves as reported in different 
studies. Studies were identified from a PubMed search using the medical subject heading (MeSH) 
terms  ‘ biological marker, urine ’ and  ‘ kidney injury, acute ’ with the limits  ‘ human ’ and  ‘ last two years. ’ 
Studies were limited to those reporting data on urinary biomarkers, except for the study by 
Shapiro  et al. 2 The numbers along the  y axis correspond to the study numbers in  Table 1 . Pink bars: 
Areas under the receiver operating characteristic curves of clinical or basic biochemistry criteria. Blue 
bars: Studies with neutrophil gelatinase-associated lipocalin (NGAL). Green bars: Studies with other 
novel biomarkers. 1 – 28: Studies with acute kidney injury as end point; 29 – 33: studies with need for 
renal replacement therapy or worsening renal function as end point; 34 – 37: studies with mortality 
as end point. 
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worse instead of better outcome for the 
patient, and, in the best case, a waste of 
money. We hope that in future studies, 
the performance of biomarkers will be 
evaluated on top of clinical and basic bio-
chemical parameters and will be coupled 
to an intervention. Th ose who believe 
they should look at the stars to guide their 
steps, risk stumbling over simple cobble-
stones before their feet on the ground. 
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